CYP3A4-Catalyzed Simvastatin Metabolism as a Non-Invasive Marker of Small Intestinal Health in Celiac Disease
- 1 August 2013
- journal article
- research article
- Published by Wolters Kluwer Health in American Journal of Gastroenterology
- Vol. 108 (8) , 1344-1351
Abstract
Histological examination of duodenal biopsies is the gold standard for assessing intestinal damage in celiac disease (CD). A noninvasive marker of disease status is necessary, because obtaining duodenal biopsies is invasive and not suitable for routine monitoring of CD patients. As the small intestine is a major site of cytochrome P450 3A4 (CYP3A4) activity and also the location of the celiac lesion, we investigated whether patients with active CD display abnormal pharmacokinetics of an orally administered CYP3A4 substrate, simvastatin (SV), which could potentially be used for noninvasive assessment of their small intestinal health. Preclinical experiments were performed in CYP3A4-humanized mice to examine the feasibility of the test. Subsequently, a clinical trial was undertaken with 11 healthy volunteers, 18 newly diagnosed patients with CD, and 25 celiac patients who had followed a gluten-free diet (GFD) for more than 1 year. The maximum concentration (Cmax) of orally administered SV plus its major non-CYP3A4-derived metabolite SV acid (SV equivalent (SVeq)) was measured, and compared with clinical, histological, and serological parameters. In CYP3A4-humanized mice, a marked decrease in SV metabolism was observed in response to enteropathy. In the clinical setting, untreated celiac patients displayed a significantly higher SVeq Cmax (46±24 nM) compared with treated patients (21±16 nM, PPeq Cmax correctly predicted the diagnosis in 16/18 untreated celiac patients, and also the recovery status of all follow-up patients that exhibited normal or near-normal biopsies (Marsh 0-2). All patients with abnormal SVeq Cmax showed a reduction in the value after 1 year of following a GFD. SVeq Cmax is a promising noninvasive marker for assessment of small intestinal health. Further studies are warranted to establish its clinical utility for assessing gut status of patients with CD.Keywords
This publication has 32 references indexed in Scilit:
- Nondietary Therapies for Celiac DiseaseGastrointestinal Endoscopy Clinics of North America, 2012
- For Celiac Disease, Diagnosis Is Not EnoughClinical Gastroenterology and Hepatology, 2012
- Future treatment strategies for celiac diseaseExpert Opinion on Therapeutic Targets, 2012
- Novel therapies for coeliac diseaseJournal of Internal Medicine, 2011
- Update on Serologic Testing in Celiac DiseaseAmerican Journal of Gastroenterology, 2010
- Celiac diseaseCurrent Opinion in Gastroenterology, 2010
- Celiac Disease: From Pathogenesis to Novel TherapiesGastroenterology, 2009
- Increasing prevalence of coeliac disease over timeAlimentary Pharmacology & Therapeutics, 2007
- Lack of Usefulness of Anti-Transglutaminase Antibodies in Assessing Histologic Recovery After Gluten-Free Diet in Celiac DiseaseJournal of Clinical Gastroenterology, 2003
- Grapefruit juice—simvastatin interaction: Effect on serum concentrations of simvastatin, simvastatin acid, and HMG-CoA reductase inhibitors*Clinical Pharmacology & Therapeutics, 1998